RU94043771A - Замещенные бензимидазольные соединения, способ лечения, фармацевтическая композиция и способ получения бензимидазольных соединений - Google Patents

Замещенные бензимидазольные соединения, способ лечения, фармацевтическая композиция и способ получения бензимидазольных соединений

Info

Publication number
RU94043771A
RU94043771A RU94043771/04A RU94043771A RU94043771A RU 94043771 A RU94043771 A RU 94043771A RU 94043771/04 A RU94043771/04 A RU 94043771/04A RU 94043771 A RU94043771 A RU 94043771A RU 94043771 A RU94043771 A RU 94043771A
Authority
RU
Russia
Prior art keywords
benzimidazole compounds
virus
synthesis
pharmaceutical composition
compounds
Prior art date
Application number
RU94043771/04A
Other languages
English (en)
Other versions
RU2141952C1 (ru
Inventor
Б. Таунсенд Лерой
Us]
Чарльз Дрэч Джон
Спенсер Гуд Стивен
Мэри Дэльюдж Сьюзн
Толар Мартин Майкл
Original Assignee
Дзе Веллкам Фаундейшн Лимитед (GB)
Дзе Веллкам Фаундейшн Лимитед
Дзе Риджентс оф дзе Юниверсити оф Мичиган (US)
Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Веллкам Фаундейшн Лимитед (GB), Дзе Веллкам Фаундейшн Лимитед, Дзе Риджентс оф дзе Юниверсити оф Мичиган (US), Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган filed Critical Дзе Веллкам Фаундейшн Лимитед (GB)
Publication of RU94043771A publication Critical patent/RU94043771A/ru
Application granted granted Critical
Publication of RU2141952C1 publication Critical patent/RU2141952C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

К особенно предпочтительным соединениям относятся такие, в которых положения 2, 5 и 6 имидазольного основания замещены галогеном. Соединения обладают активностью против вируса герпеса, особенно вируса цитомегалии, а также против инфекций вирусом гепатита В.

Claims (1)

  1. К особенно предпочтительным соединениям относятся такие, в которых положения 2, 5 и 6 имидазольного основания замещены галогеном. Соединения обладают активностью против вируса герпеса, особенно вируса цитомегалии, а также против инфекций вирусом гепатита В.
RU94043771A 1992-03-09 1993-03-08 Замещенные бензимидазольные соединения, способы получения и фармацевтическая композиция на их основе, обладающая антивирусным действием RU2141952C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929205071A GB9205071D0 (en) 1992-03-09 1992-03-09 Therapeutic nucleosides
GB9205071.5 1992-03-09
PCT/GB1993/000479 WO1993018009A1 (en) 1992-03-09 1993-03-08 Antiviral nucleoside analogues

Publications (2)

Publication Number Publication Date
RU94043771A true RU94043771A (ru) 1996-08-10
RU2141952C1 RU2141952C1 (ru) 1999-11-27

Family

ID=10711750

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94043771A RU2141952C1 (ru) 1992-03-09 1993-03-08 Замещенные бензимидазольные соединения, способы получения и фармацевтическая композиция на их основе, обладающая антивирусным действием

Country Status (20)

Country Link
US (1) US5534535A (ru)
EP (1) EP0630368B1 (ru)
JP (1) JP3450854B2 (ru)
KR (2) KR950700887A (ru)
AT (1) ATE170846T1 (ru)
AU (1) AU672597B2 (ru)
CA (1) CA2131693A1 (ru)
CZ (1) CZ209494A3 (ru)
DE (1) DE69320945T2 (ru)
DK (1) DK0630368T3 (ru)
ES (1) ES2123048T3 (ru)
FI (1) FI944134A (ru)
GB (1) GB9205071D0 (ru)
HU (1) HUT68445A (ru)
IL (1) IL104976A (ru)
NZ (1) NZ249554A (ru)
RU (1) RU2141952C1 (ru)
TW (1) TW366339B (ru)
WO (1) WO1993018009A1 (ru)
ZA (1) ZA931647B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9205071D0 (en) * 1992-03-09 1992-04-22 Wellcome Found Therapeutic nucleosides
GB9413724D0 (en) * 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides
PL319440A1 (en) * 1994-09-09 1997-08-04 Wellcome Found Analoques of antiviral nuceosides containing substituted benzimidazoles attached to the carbocyclic ring
US5811073A (en) * 1995-06-19 1998-09-22 President And Fellows Of Harvard College Method for radioisotopic detection and localization of inflammation in a host
US5912356A (en) * 1995-09-11 1999-06-15 Glaxo Wellcome Inc. Antiviral nucleoside analogues containing a substituted benzimidazole base attached to a carbocyclic ring
GB9600142D0 (en) * 1996-01-05 1996-03-06 Wellcome Found Chemical compounds
GB9600143D0 (en) 1996-01-05 1996-03-06 Wellcome Found Therapeutic compounds
DE69819695D1 (en) 1997-02-13 2003-12-18 Glaxo Group Ltd Benzimidazolderivate
SK285228B6 (sk) * 1997-05-13 2006-09-07 Lonza Ag Spôsob výroby racemického alebo opticky aktívnehoderivátu 4-(hydroxymetyl)-2-cyklopenténu a racemicky N-butyryl-1-amino-4- (hydroxymetyl)-2-cyklopentén
DK0994890T3 (da) 1997-06-10 2003-12-01 Univ Michigan Benzimidazolderivater
NZ502882A (en) 1997-07-30 2002-02-01 Glaxo Group Ltd Lyxofuranosyl benzimidazoles as antiviral agents
US6514979B1 (en) 1999-03-03 2003-02-04 University Of Maryland Biotechnology Institute Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
GB0008939D0 (en) 2000-04-11 2000-05-31 Glaxo Group Ltd Process for preparing substituted benzimidazole compounds
AU2001259068A1 (en) 2000-04-13 2001-10-30 Pharmasset, Ltd. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
CN106243111B (zh) * 2007-08-02 2019-07-23 米伦纽姆医药公司 合成e1活化酶抑制剂的方法
KR101608259B1 (ko) 2008-04-28 2016-04-01 교린 세이야꾸 가부시키 가이샤 시클로펜틸아크릴산아미드 유도체
US11499722B2 (en) * 2020-04-30 2022-11-15 Bsh Home Appliances Corporation Household cooking appliance having an oven door with an interior camera

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996308A (en) * 1988-03-25 1991-02-26 Merrell Dow Pharmaceuticals Inc. Derivatives with unsaturated substitutions for the 5'-hydroxymethyl group
ZA894534B (en) * 1988-06-20 1990-03-28 Merrell Dow Pharma Novel neplanocin derivatives
GB8826205D0 (en) * 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
GB8926417D0 (en) * 1989-11-22 1990-01-10 Wellcome Found Heterocyclic compounds
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
US5248672A (en) * 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
GB9205071D0 (en) * 1992-03-09 1992-04-22 Wellcome Found Therapeutic nucleosides

Also Published As

Publication number Publication date
JPH07506816A (ja) 1995-07-27
WO1993018009A1 (en) 1993-09-16
FI944134A (fi) 1994-11-07
AU672597B2 (en) 1996-10-10
US5534535A (en) 1996-07-09
KR950700887A (ko) 1995-02-20
HUT68445A (en) 1995-06-28
CA2131693A1 (en) 1993-09-16
DK0630368T3 (da) 1999-06-07
CZ209494A3 (en) 1995-11-15
ZA931647B (en) 1994-09-08
GB9205071D0 (en) 1992-04-22
DE69320945T2 (de) 1999-02-04
NZ249554A (en) 1996-05-28
DE69320945D1 (de) 1998-10-15
KR970705547A (ko) 1997-10-09
ES2123048T3 (es) 1999-01-01
FI944134A0 (fi) 1994-09-08
EP0630368B1 (en) 1998-09-09
HU9402582D0 (en) 1994-11-28
RU2141952C1 (ru) 1999-11-27
ATE170846T1 (de) 1998-09-15
IL104976A (en) 1998-10-30
IL104976A0 (en) 1993-07-08
JP3450854B2 (ja) 2003-09-29
TW366339B (en) 1999-08-11
AU3643293A (en) 1993-10-05
EP0630368A1 (en) 1994-12-28

Similar Documents

Publication Publication Date Title
RU94043771A (ru) Замещенные бензимидазольные соединения, способ лечения, фармацевтическая композиция и способ получения бензимидазольных соединений
EA199901031A1 (ru) Производные бензимидазола
NL300247I2 (nl) 2-Halogeen-9-(2-desoxy-2-fluor-bêta-D-arabinofuranosyl)-adeninenucleosiderivaten.
EA199800943A1 (ru) Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы
RU94046306A (ru) Производные индолокарбазолимида, смесь их изомеров или отдельные изомеры и их соли и фармацевтическая композиция с активностью, ингибирующей протеинкиназу с или киназу легкой миозиновой цепи или подавляющей иммунные реакции
ES2067508T3 (es) Dihidroisoquinolinonas sustituidas y compuestos relacionados como potenciadores de los efectos letales de la radiacion y de ciertos agentes quimioterapeuticos; compuestos seleccionados, analogos y proceso.
KR950700298A (ko) 뉴클레오시드 치료제(Therapeutic Nucleosides)
PA8483101A1 (es) Compuestos quimicos
EA200400735A1 (ru) 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
EA200200247A1 (ru) Производные арилметилкарбониламинотиазола и их применение в качестве противоопухолевых средств
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
RU95108243A (ru) Производные амидов вальпроновой и 2-вальпроеновой кислоты, фармацевтическая композиция, способы лечения
ATE135011T1 (de) Therapeutische nukleoside
ATE20748T1 (de) Guaninderivate.
SE8900192L (sv) Dideoxididehydrokarbocykliska nukleosider
KR880013937A (ko) 옥세타노신 유도체
RU94038256A (ru) Производные пиразолопиримидина, способ их получения, фармацевтические композиции на их основе
DK468288D0 (da) Antivirale forbindelser
RU94035964A (ru) Производные бензопирана, фармацевтическая композиция на их основе, способ их получения, способ лечения и способ получения промежуточного продукта
KR900700495A (ko) 치료제로서 유용한 치환된 아데닌 유도체
RU94039545A (ru) Новые производные аденозина, способы их получения, фармацевтические композиции на их основе, способы получения фармацевтических композиций и их применение
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
KR900009083A (ko) 2', 3'-디데옥시푸린 뉴클레오사이드/푸린 뉴클레오 사이드 포스포릴라제 억제제 배합 치료법 및 조성물
DK178188D0 (da) Antivirusmiddel
ES2105923A1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).